RePer-AGE: Reorganization of Visuo-cognitive Functions Based on Peripheral Vision With Aging (NCT07727369) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
RePer-AGE: Reorganization of Visuo-cognitive Functions Based on Peripheral Vision With Aging
France160 participantsStarted 2026-09-01
Plain-language summary
The RePer-AGE study investigates how central and peripheral vision contribute to visual recognition and how these mechanisms change with normal aging. The study is based on the hypothesis that peripheral vision provides rapid global information that supports visual recognition through predictive mechanisms. Healthy young adults (18-30 years) and older adults (60-85 years) will undergo visual psychophysical testing, ophthalmological examinations, and, for a subset of participants, functional magnetic resonance imaging (fMRI). The results are expected to improve our understanding of age-related changes in visuo-cognitive functions and provide reference data for future studies on age-related visual disorders.
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy young adults aged 18 to 30 years or healthy older adults aged 60 to 85 years.
* Normal or corrected-to-normal visual acuity.
* No ophthalmological disease affecting visual function.
* For participants aged 60 years or older: Mini-Mental State Examination (MMSE) score ≥23.
* Affiliated with a national health insurance system.
* Written informed consent.
Non inclusion Criteria:
* Individuals protected under French regulations governing research involving human participants.
* Employees or individuals under the direct authority of the investigators.
* History of neurological or psychiatric disorders likely to affect visual or cognitive functions.
* Current treatment likely to alter visual function or vigilance.
* MRI contraindications (metallic implants, pacemaker, severe claustrophobia, or other MRI safety contraindications) for participation in the MRI arm only.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Behavioral performance during scene categorization tasks